Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6616 to 6630 of 8905 results

  1. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

  2. Surgical vessel sealing systems (MT798)

    In development Reference number: GID-MT594 Expected publication date: TBC

  3. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

  4. Inpatient mental health settings

    Discontinued Reference number: GID-SGWAVE0701

  5. Mental health community settings

    Discontinued Reference number: GID-SGWAVE0702

  6. Management and organisational approaches to safe staffing

    Discontinued Reference number: GID-SGWAVE0761

  7. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued Reference number: GID-TA10026

  8. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

  9. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

  10. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

  11. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

  12. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued Reference number: GID-TA10065

  13. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

  14. Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

    Discontinued Reference number: GID-TA10070

  15. Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]

    Discontinued Reference number: GID-TA10074